vzphotos/iStock Editorial by way of Getty Photos
- French drugmaker MedinCell (OTC:MDCLF) introduced Tuesday a partnership with AbbVie (NYSE:ABBV) to co-develop and commercialize long-acting injectables in a deal value as much as $1.9B.
- Per the phrases, the corporate will leverage its commercial-stage long-acting injectable expertise platform to develop as much as six therapeutics throughout a number of medical indications.
- Whereas MedinCell (OTC:MDCLF) might be chargeable for early-stage research, AbbVie (ABBV) will take over their medical and late-stage growth, together with regulatory approval, manufacturing, and commercialization.
- In alternate, AbbVie (ABBV) can pay MedinCell (OTC:MDCLF) $35M upfront, as much as $1.9B in growth and industrial milestones, and mid-single to low-double-digit royalties on web gross sales.
- Up to now, the Jacou, France-based firm, in collaboration with Teva (TEVA), has used its drug supply expertise BEPO to develop Uzedy, a long-acting injectable authorized for schizophrenia in adults.
